Sweden’s Sobi and US biopharma Apellis Pharmaceuticals have presented new data from the open-label period of the Phase III ...

Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating Aspaveli® (pegcetacoplan) for C3 glomerulopathy (C3G ...

Robust proteinuria reduction and stable kidney function were maintained across a broad population of patients No new safety signals were observedNew data presented at late-breaking session at the ...

The VALIANT Phase 3 trial shows that pegcetacoplan significantly reduces proteinuria and stabilises kidney function in ...

Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating Aspaveli® ...

Early detection and new biomarkers are changing how we manage acute kidney injury—and its link to chronic kidney disease.

Glomerulonephritis is a type of kidney disease linked to inflammation of the tiny blood vessels in the kidneys known as glomeruli. It can result from streptococcal infections, certain diseases ...

Vicky Ograin, MBA, RVT, VTS (Nutrition), discussed the gastrointestinal microbiome and how it can be modulated with ...

The FDA is expected to decide on treatments for multiple myeloma, NSCLC, melanoma, phenylketonuria, and 2 rare kidney diseases.

The causes of kidney damage are varied, but more or less include Chronic Kidney Disease (CKD), Acute Kidney Injury, Diabetes, ...

Even if there are problems with the function, the kidneys do not have any special symptoms, making it difficult to recognize ...

Aptar Digital Health has signed a licensing agreement with AstraZeneca for detecting CKD using the latter’s AI-driven ...